Ovagen
Peptide Bioregulator
Also known as Liver/ovary peptide bioregulator
Ovagen is a short synthetic peptide of the bioregulator class, studied in research within the framework of tissue-specific short-peptide regulators.
This product is intended strictly for laboratory research use within the United States. It is not approved by the FDA for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable U.S. federal, state, and local regulations.
Ovagen is a short synthetic peptide of the bioregulator class, studied in research within the framework of tissue-specific short-peptide regulators.
Experimental framing draws on the broader peptide-bioregulator literature, as direct studies are limited.
Third-party tested for purity, ID, quantity.
Ovagen belongs to the family of short peptide bioregulators investigated for proposed tissue-specific regulatory activity. Direct published research on Ovagen specifically is minimal; the compound is framed within the broader short-peptide-bioregulator research field, including work on gene-expression and protein-synthesis regulation by short peptides.
Research context is provided by class-level studies rather than compound-specific trials.
Ovagen arises from research programs into short regulatory peptides proposed to act on specific tissues.
Compound-specific literature is effectively absent; context derives from the short-peptide-bioregulator field.
Direct research on Ovagen is minimal. Context is drawn from the short-peptide-bioregulator literature on gene-expression and protein-synthesis regulation. Reference support is thin and class-level rather than compound-specific.
3 of the 3 areas below are addressed directly by a paper cited on this page.
Short-peptide bioregulator class models
Addressed on this page by Umnov 2013, Khavinson 2020. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Umnov, RS. et al. (2013) — [Neuroprotective effects of peptides bioregulators in people of various age]
- Khavinson, V. et al. (2020) — EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease
Gene-expression regulation by short peptides
Addressed on this page by Khavinson 2020, Umnov 2013. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Khavinson, V. et al. (2020) — EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease
- Umnov, RS. et al. (2013) — [Neuroprotective effects of peptides bioregulators in people of various age]
Tissue-specific peptide research frameworks
Addressed on this page by Khavinson 2020, Umnov 2013. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Khavinson, V. et al. (2020) — EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease
- Umnov, RS. et al. (2013) — [Neuroprotective effects of peptides bioregulators in people of various age]
The references section of this page cites 2 primary papers published between 2013 and 2020 — a thin record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Ovagen is frequently listed as a peptide by suppliers in this market. It is not one. The structure published on this page is the compound's actual chemistry, and research on it should be read against its own class rather than against peptide literature.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for Ovagen, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
Ovagen is commonly described online in connection with faster healing from injury and improved recovery. In the research literature the same compound is filed under short-peptide bioregulator class models, gene-expression regulation by short peptides and tissue-specific peptide research frameworks.
The 2 papers cited on this page, published between 2013 and 2020 describe laboratory and animal work. None reports a controlled trial in humans. Findings in cell culture or in a rodent model describe what happened in that system; they do not establish that the same occurs in humans, and this compound is not approved for human use.
Presented alongside compounds with decades of published research, as though the evidence base is comparable.
It is not. Ovagen rests on 2 cited papers (between 2013 and 2020). A record that thin cannot support conclusions about mechanism, effect or safety, and the honest reading is that this compound has been studied very little rather than studied and validated.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Every lot of Ovagen is independently assayed before it is released, and the certificate for the lot shipped is published rather than summarised. Where a certificate for a current lot is not yet posted, the lot has not yet been released against it.
Researchers who buy Ovagen in the United States through Eppix Labs receive a batch-labelled vial whose certificate is published against that lot code, so the material can be matched to its analysis rather than to a generic specification.
- Lyophilized storage
- −20 °C long-term; stable at room temperature in transit
- After reconstitution
- 2–8 °C
- Light
- Protect from UV and direct light
- Freeze-thaw
- Avoid repeated cycles
- Vehicle
- Solvent selection depends on the compound; consult the published literature
- Format
- Lyophilized powder
Ovagen is supplied as lyophilized powder. It is not a peptide, and solvent behaviour follows from its own chemistry rather than from the aqueous-vehicle conventions that apply to peptide material — the published literature for this compound is the reference for solvent selection, not a general peptide protocol.
Dry storage below freezing and protection from light are the general controls. As with any lyophilized material, the powder frequently sits as a thin film at the base of the vial and is easy to mistake for an empty vial before inspection.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
- 1 × sealed glass vial in the strength selected (20mg / Single Vial, 20mg / 5-Pack, 20mg / 10-Pack available), batch-labelled
- Batch documentation for the lot shipped, once its certificate is published
- Discreet outer packaging with no product names on the exterior
- FedEx, tracked, typically 1–3 business days domestically
- Bacteriostatic water or any other reconstitution vehicle
- Syringes, needles or filters
- Dosing, administration or protocol guidance of any kind
Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each unit contains the labeled quantity of ovagen. Independent third-party analysis verifies purity, identity, and net content per batch.
The unit contains only the research compound. Any laboratory materials required for reconstitution or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
Related
You May Also Like
Next-generation GLP receptor agonist studied for metabolic signaling and nutrient partitioning pathways
From$79.99
Dual incretin receptor agonist studied for glucose regulation, metabolic signaling, and weight pathway research
From$39.99
Studied in metabolic research for its effects on glucose regulation, appetite signaling, and energy balance.
From$59.99
Long-acting amylin analog engineered for appetite signaling, metabolic control, and energy balance research
From$99.99